Advertisement

Uses, Overuses, and Problems Associated with the Implantable Defibrillator

  • J. Anthony GomesEmail author
Chapter
  • 31 Downloads

Abstract

Since the invention of the internal cardioverter defibrillator (ICD) in the 1980s, there has been a marked increase in the rate of ICD implants, as data from secondary and primary prevention trials accumulated. The increase has mostly occurred for primary prevention ICDs which account for nearly 80% of all ICD implants in the USA. Over these three decades, we have learned much from long-term follow-up of patients with ICDs. This chapter discusses the current indications and contraindications of ICDs, survival of patients receiving a primary prevention ICD in clinical practice versus clinical trials, misuses of ICDs, and complications resulting from ICD use.

Keywords

Internal cardioverter defibrillator New York Heart Association (NYHA) Sudden cardiac death (SCD) Ejection fraction (EF) Guideline-directed medical therapy (GDMT) Chronic kidney disease (CKD) Lead fractures Inappropriate shocks (IAS) 

References

  1. 1.
    Epstein AE, Kay GN, Plumb VJ, et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009;6:1136–43.PubMedGoogle Scholar
  2. 2.
    Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm. 2018;15(10):e73–189.PubMedGoogle Scholar
  3. 3.
    Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy. J Am Coll Cardiol. 2013;61(12):1320–64.Google Scholar
  4. 4.
    Al-Khatib SM, Helpkemp A, Bardy GH, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013;309(1):55–62.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009–a world society of arrhythmia’s project. PACE. 2011;34(8):1013–27.PubMedGoogle Scholar
  6. 6.
    Camm AJ, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the ‘enigma’? Europace. 2010;12:1063–9.Google Scholar
  7. 7.
    Silverstein JR, Katritsis DG, Josephson ME. Use and abuse of internal cardioverter defibrillators for primary prevention. Arrhythm Electrophysiol Rev. 2012;1:46–50.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Gomes JA, Mehta D, Ip J, Winters S, Camunas J, Ergin A, Newhouse T, Pe E. Predictors of long - term survival in patients with malignant ventricular arrhythmias. Am J Cardiol. 1997;79:1054–60.PubMedGoogle Scholar
  9. 9.
    Buxton AE, Lee KL, Hafley GE, et al. MUSTT investigators: limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50:1150–7.PubMedGoogle Scholar
  10. 10.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40. [PMID: 8960472].PubMedPubMedCentralGoogle Scholar
  11. 11.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90.PubMedGoogle Scholar
  12. 12.
    Moss AJ, Zareba W, Hall WJ, Multicenter Automatic Defibrillator Implantation Trial II Investigators, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Panotopoulos PT, Axtell K, Anderson AJ, et al. Efficacy of implantable cardioverter-defibrillator in the elderly. J Am Coll Cardiol. 1997;29(3):556–60.PubMedGoogle Scholar
  15. 15.
    Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening arrhythmias. Eur Heart J. 2007;28:1746–9.PubMedGoogle Scholar
  16. 16.
    Brüllmann S, Dichtl W, Paoli U, et al. Comparison of benefit and mortality of implantable cardioverter-defibrillator therapy in patients aged ≥75 years versus those <75 years. Am J Cardiol. 2012;109(5):712–7.PubMedGoogle Scholar
  17. 17.
    Krahn AD, Connolly SJ, Roberts RS, Gent M. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J. 2004;147:837–40.PubMedGoogle Scholar
  18. 18.
    Goldenberg I, Vyas AK, Hall WJ, MADIT-II Investigators, et al. Risk stratification for primary prevention of a cardioverter defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–96.PubMedGoogle Scholar
  19. 19.
    US Renal Data System. USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.Google Scholar
  20. 20.
    Hess PL, Hellkemo AS, Peterson ED. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. Circ Arrhythm Electrophysiol. 2014;7:793–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Patton KK, Poole JE. Defibrillator therapy in chronic kidney disease: is it worth it? Circ Arrhythm Electrophysiol. 2014;7:774–6.PubMedGoogle Scholar
  22. 22.
    Sakhuja R, Keebler M, Lai T-S, et al. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol. 2009;103(5):735–41.PubMedGoogle Scholar
  23. 23.
    Ezzat VA, Lee V, Ahsan S, et al. A systematic review of ICD complications in randomised controlled trials versus registries: is our ‘real-world’ data an underestimation? Open Heart. 2015;2:e000198.  https://doi.org/10.1136/openhrt-2014-0001981.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tarakji KG, Ellis CR, Defaye P, Kennergren C. Cardiac implantable electronic device infection in patients at risk. Arrhythm Electrophysiol Rev. 2016;5(1):65–71.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Bloom H, Heeke B, Leon A. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol. 2006;29(2):142–5.PubMedGoogle Scholar
  26. 26.
    Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures results from the REPLACE registry. Circulation. 2010;122:1553–61.Google Scholar
  27. 27.
    Hauser RG, Hayes DL. Increasing hazard of sprint fidelis implantable cardioverter-defibrillator lead failure. Heart Rhythm. 2009;6:605–10.PubMedGoogle Scholar
  28. 28.
    Hauser RG, McGriff D, Retel LK. Riata implantable cardioverter-defibrillator lead failure. Heart Rhythm. 2012;9:742–9.PubMedGoogle Scholar
  29. 29.
    Maytin M, Love CJ, Fisher A, et al. Multicenter experience with extraction of the sprint fidelis implantable cardioverter-defibrillator lead. J Am Coll Cardiol. 2010;56:646–50.PubMedGoogle Scholar
  30. 30.
    Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, Howlett JG, Kautzner J, Love CJ, Morgan JM, Priori SG, Reynolds DW, Schoenfeld MH, Vardas PE, Heart Rhythm Society, European Heart Rhythm Association, American College of Cardiology, American Heart Association, European Society of Cardiology, Heart Failure Association of ESC, Heart Failure Society of America. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm. 2008;5:907–25.PubMedGoogle Scholar
  31. 31.
    Daubert JP, Zareba W, Cannon DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II. J Am Coll Cardiol. 2008;51:1357–65.PubMedGoogle Scholar
  32. 32.
    Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Johannes van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, Schalij MJ. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57(5):556–62.PubMedGoogle Scholar
  34. 34.
    Dichtl W, Wolber T, Paoli U, et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clin Cardiol. 2011;7:433–6.Google Scholar
  35. 35.
    Powell BD, Saxon LA, Boehmer JP, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol. 2013;62(18):1674–9.PubMedGoogle Scholar
  36. 36.
    Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367(24):2275–28.PubMedGoogle Scholar
  37. 37.
    Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the ide study and effortless registry. J Am Coll Cardiol. 2015;65:1605–15.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Boersma L, Barr C, Knops R, et al. Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry: the effortless study. J Am Coll Cardiol. 2017;70:830–41.PubMedGoogle Scholar
  39. 39.
    Knops RE, Brouwer TF, Barr CS, et al. The learning curve associated with the introduction of the subcutaneous implantable defibrillator. EP Europace. 2016;18:1010–5.Google Scholar
  40. 40.
    Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the effortless S-ICD registry. Eur Heart J. 2014;35:1657–65.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944–53.PubMedGoogle Scholar
  42. 42.
    Athan E, Chu VH, Tattevin P, et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA. 2012;307:1727–35.PubMedGoogle Scholar
  43. 43.
    Wilkoff BL. Lead-induced venous thrombosis: consequences? J Cardiovasc Electrophysiol. 2004;15:1263–4.PubMedGoogle Scholar
  44. 44.
    Miller MA, Bhatt HV, Weiner M, et al. Implantation of the subcutaneous implantable cardioverter–defibrillator with truncal plane blocks. Heart Rhythm. 2018;15:1108–11.PubMedGoogle Scholar
  45. 45.
    Brisben AJ, Burke MC, Knight BP, et al. A new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc Electrophysiol. 2015;26:417–23.PubMedGoogle Scholar
  46. 46.
    Gehi AK, Mehta D, Gomes JA. Evaluation and management of patients after implantable cardioverter-defibrillator shock. JAMA. 2006;296:1839–2847.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Icahn School of MedicineMount Sinai HospitalNew YorkUSA

Personalised recommendations